CRNX
$24.40
Crinetics Pharmaceuticals
($3.08)
(11.21%)
CRNX
Earnings Whisper ®
N/A
4th Quarter December 2021
Consensus:  ($0.60)
Revenue:  N/A
Friday
Feb 4
8:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when CRNX reports earnings?
Beat
Meet
Miss

Where is CRNX's stock price going from here?
Up
Flat
Down
Stock chart of CRNX
Analysts
Summary of analysts' recommendations for CRNX
Score
Grade
Pivots
Resistance
$31.32
$29.63
$27.02

$25.33

Support
$22.72
$21.03
$18.42
Tweet
Growth
Description
Crinetics Pharmaceuticals Inc is a clinical stage pharmaceutical company. It focuses on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's product pipeline consists of CRN00808 for the treatment of Acromegaly, CRN02481 for the treatment of Hyperinsulinemias and CRN01941 for the treatment of Neuroendocrine Tumors which are in clinical stage. Crinetics Pharmaceuticals Inc is based in San Diego, United States.